- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pulmonx Corp (LUNG)
The Pulmonx share price today is 2.28, view NASDAQ LUNG stock exchange data. Track the latest Pulmonx share price with real-time updates on LUNG stock performance including market cap, day range, 52-week range and dividend yield. Access LUNG charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.03
2.37
52 wk Range
1.13
2.89
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.032.37
52 wk Range
1.132.89
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LUNG Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
3.40
Upside
+49.12%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Pulmonx Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
Form DEF 14A PULMONX CORPORATION For: 22 April- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 3.40
(+49.12% Upside)
Pulmonx Corp Earnings Call Summary for Q2/2026
- Pulmonx beat Q2 2026 estimates with adjusted loss of $0.24/share vs. $0.28 expected; revenue reached $22.8M, topping $22.41M forecast; shares surged 14.4%.
- Gross margin expanded to 78% from 72% YoY; adjusted EBITDA loss narrowed 40% to $5.1M as operating expenses fell 16% to $26.8M through cost-cutting measures.
- Revenue declined 5% YoY to $22.8M amid softer U.S. and international sales; company added 12 new U.S. treatment centers, targeting 40 annually.
- Management maintained 2026 revenue guidance at $90M-$92M, expects double-digit growth by year-end; China revenue anticipated in early 2027 after registration renewal.
- Cash position of $55.8M supports operations; full-year cash burn expected at $23M, down 30% from 2025, with gross margin outlook maintained at 76%.
Last Updated: 30-07-2026, 02:54 am
Read Full TranscriptEarnings
Latest Release
29-07-2026
EPS / Forecast
-0.24 / -0.28
Revenue / Forecast
22.8M / 22.41M
Compare LUNG to Peers and Sector
Metrics to compare | LUNG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLUNGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.0x | −1.2x | −0.4x | |
PEG Ratio | −0.09 | −0.20 | 0.00 | |
Price/Book | 2.5x | 2.7x | 2.6x | |
Price / LTM Sales | 1.1x | 2.4x | 3.1x | |
Upside (Analyst Target) | 47.1% | 64.3% | 48.2% | |
Fair Value Upside | Unlock | 17.8% | 5.8% | Unlock |
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Pulmonx (LUNG) Share Price Today?
The Pulmonx share price today is 2.28.
What is the current Pulmonx (LUNG) share price and day range?
As of 11-08-2026, the Pulmonx share price is 2.28, with a previous close of 2.28. The share price has ranged from 2.03 to 2.37 today, while the 52-week range spans from 1.13 to 2.89.
What Is the Pulmonx Market Cap?
As of today, Pulmonx market cap is 97.92M.
What Is the Pulmonx (LUNG) Share Price Target?
The average 12-month share price target for Pulmonx is 3.40, with a high estimate of 5 and a low estimate of 2.5. 3 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +49.12% Upside potential.
What Is Pulmonx's Earnings Per Share (TTM)?
The Pulmonx EPS (TTM) is -1.15.
When Is the Next Pulmonx Earnings Date?
Pulmonx will release its next earnings report on 04-11-2026.
From a Technical Analysis Perspective, Is LUNG a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Pulmonx Trade On?
Pulmonx is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Pulmonx?
The stock symbol for Pulmonx is "LUNG."
How Many Times Has Pulmonx Stock Split?
Pulmonx has split 0 times.
How Many Employees Does Pulmonx Have?
Pulmonx has 296 employees.
What Is the LUNG After Hours Price?
LUNG's last after hours stock price is 2.35, the stock has changed by 0.07, or 3.07%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.